Morgan Stanley’s Rallybio RLYB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2K Sell
125
-1
-0.8% -$13 ﹤0.01% 7407
2026
Q1
$1.13K Sell
126
-454
-78% -$3.1K ﹤0.01% 7417
2025
Q4
$3.18K Hold
580
﹤0.01% 7154
2025
Q3
$2.31K Sell
580
-3,981
-87% -$16.7K ﹤0.01% 7276
2025
Q2
$12.3K Hold
4,561
﹤0.01% 6793
2025
Q1
$23.9K Hold
4,561
﹤0.01% 6511
2024
Q4
$35K Hold
4,561
﹤0.01% 6397
2024
Q3
$42.7K Sell
4,561
-2,325
-34% -$22.4K ﹤0.01% 6265
2024
Q2
$73.8K Sell
6,886
-2,662
-28% -$36.1K ﹤0.01% 6060
2024
Q1
$141K Sell
9,548
-2,842
-23% -$39.6K ﹤0.01% 5864
2023
Q4
$237K Buy
12,390
+10,418
+528% +$255K ﹤0.01% 5634
2023
Q3
$53.2K Sell
1,972
-768
-28% -$33.3K ﹤0.01% 6143
2023
Q2
$124K Buy
2,740
+1,573
+135% +$77.1K ﹤0.01% 5851
2023
Q1
$53.3K Buy
1,167
+964
+475% +$49.8K ﹤0.01% 6265
2022
Q4
$10.7K Sell
203
-606
-75% -$35.8K ﹤0.01% 6909
2022
Q3
$94K Sell
809
-209
-21% -$18.6K ﹤0.01% 6113
2022
Q2
$61K Sell
1,018
-209
-17% -$15.7K ﹤0.01% 6520
2022
Q1
$69K Buy
1,227
+240
+24% +$19.9K ﹤0.01% 6535
2021
Q4
$76K Buy
987
+718
+267% +$83.5K ﹤0.01% 6596
2021
Q3
$38K Buy
+269
New +$31.6K ﹤0.01% 6834

Other funds holding RLYB

Morgan Stanley's RLYB Position: Q2 2026 in Review

Morgan Stanley reduced its Rallybio (RLYB) stake by 0.79% in Q2 2026, selling an estimated $13 and leaving 125 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #7407.

Morgan Stanley first reported a position in RLYB in Q3 2021 and has held it in 20 quarters since. The position peaked at $237K in Q4 2023. 37 funds tracked by Wall St. Rank hold RLYB as of Q2 2026.

  • Morgan Stanley held 125 shares of Rallybio worth $2K as of Q2 2026.
  • Morgan Stanley sold 1 Rallybio share in Q2 2026, an estimated $13.
  • Rallybio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7407 holding.
  • Morgan Stanley first reported a position in Rallybio in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Rallybio position peaked at $237K in Q4 2023.
  • 37 funds tracked by Wall St. Rank held Rallybio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.